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Genetic deficiency of neuronal RAGE protects against
AGE-induced synaptic injury
Hongju Zhang1,2,3, Yongfu Wang1,3, Shijun Yan1, Fang Du1, Long Wu1, Shiqiang Yan2 and Shirley S Yan*,1
Synaptic dysfunction and degeneration is an early pathological feature of aging and age-related diseases, including Alzheimer’s
disease (AD). Aging is associated with increased generation and deposition of advanced glycation endproducts (AGEs),
resulting from nonenzymatic glycation (or oxidation) proteins and lipids. AGE formation is accelerated in diabetes and AD-
affected brain, contributing to cellular perturbation. The extent of AGEs’ involvement, if at all, in alterations in synaptic structure
and function is currently unknown. Here we analyze the contribution of neuronal receptor of AGEs (RAGE) signaling to AGE-
mediated synaptic injury using novel transgenic neuronal RAGE knockout mice specifically targeted to the forebrain and
transgenic mice expressing neuronal dominant-negative RAGE (DN-RAGE). Addition of AGEs to brain slices impaired
hippocampal long-term potentiation (LTP). Similarly, treatment of hippocampal neurons with AGEs significantly decreases
synaptic density. Such detrimental effects are largely reversed by genetic RAGE depletion. Notably, brain slices from mice with
neuronal RAGE deficiency or DN-RAGE are resistant to AGE-induced LTP deficit. Further, RAGE deficiency or DN-RAGE blocks
AGE-induced activation of p38 signaling. Taken together, these data show that neuronal RAGE functions as a signal transducer
for AGE-induced synaptic dysfunction, thereby providing new insights into a mechanism by which the AGEs–RAGE-dependent
signaling cascade contributes to synaptic injury via the p38 MAP kinase signal transduction pathway. Thus, RAGE blockade may
be a target for development of interventions aimed at preventing the progression of cognitive decline in aging and age-related
neurodegenerative diseases.
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Advanced glycation endproducts (AGEs) are members of a
heterogeneous class of molecules, which modify cellular
function by distinct mechanisms, including ligation and
activation of signal transduction receptors. The products of
non-enzymatic glycation (or oxidation) of proteins and lipids,
AGEs contribute to the normal aging process and when
accelerated have a causative role in the vasculature
complications of diabetes mellitus and several neurodegen-
erative diseases, including Alzheimer’s (AD), Parkinson’s,
and Huntington’s diseases.1–5 In diabetic patients, the
concentration of circulating AGEs (serum AGE level) has
been reported at 7.2–22 mU/ml (equivalent to 30–88 mg/ml
AGE-BSA), which is significantly higher than that of
non-diabetic patients (3 mU/ml, equivalent to 12mg/ml
AGE-BSA).6–8 The brain AGE level was also increased to
5-6mM (equivalent to 325–390mg/ml AGE-BSA) in the diabetic
animal model.9 Excess AGE accumulation is detrimental to
neurons and is believed to be a key to the pathogenesis of
cognitive decline in normal aging and specific chronic
diseases of aging. For example, in a recent clinical study,
peripheral AGE levels were associated with cognitive decline
in older adults with and without diabetes.10 Diabetes
complications affect the brain, increasing risk for depression,
dementia, and AD. In fact, patients with type 2 diabetes are at
twofold to threefold increased relative risk for AD11–18 and
accelerated cognitive dysfunction.
Long-lived proteins such as b-amyloid peptide (Ab) and
hyperphosphorylated tau protein that accumulate in AD brain
are highly susceptible to AGE modification.19–22 AGE-
modified Ab or tau protein results in increased oxidative
stress and chronic inflammation, accelerating AD pathology
and neuronal perturbation.19,20,22–25 Moreover, Ab or tau
glycation results in increased aggregation and subsequent
formation of senile plaques or neurofibrillary tangles, the
major pathological feature of AD,19,22 suggesting that AGE
modification is an important risk factor for neurodegenerative
diseases.26 Although increased accumulation of AGEs in
brain, as seen in aging, diabetes, or neurodegenerative
diseases, speeds up oxidative damage to neurons contributing
to synaptic dysfunction and cognitive decline, its underlying
mechanisms are not well understood.
Receptor for advanced glycation endproduct (RAGE) was
first identified as a cell surface receptor of the immunoglobulin
superfamily for AGEs.27,28 Increased expression of RAGE
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occurs in neuronal and non-neuronal cells in the peripheral
and central nervous system in aging, diabetes, and AD-
affected individuals, where RAGE ligands are upregu-
lated.29,30 Although it has been shown that AGEs–RAGE
interaction contributes to cellular perturbation relevant to the
pathogenesis of the cardiovascular disease and the diabetes
vascular complications,31–33 little is known about the role of
AGEs and its interaction with RAGE on synaptic dysfunction.
To understand the mechanisms involved in AGE-mediated
synaptic damage, the following questions need to be
addressed: (1) ‘Do AGEs alter synaptic structure and
function? If so, are these changes dependent on RAGE
signaling?’; (2) ‘Does RAGE blockage by genetic depletion
protect from AGE-induced synaptic dysfunction and loss?’;
and (3) ‘What is the impact of neuronal RAGE in AGE-induced
aberrant synaptic function?’. Thus it is important to evaluate
the impact of AGEs–RAGE interaction on synaptic dysfunc-
tion and to explore the mechanism underlying AGE–RAGE-
dependent signal transduction and its contribution to synaptic
damage.
Here we investigate neuronal RAGE signaling in AGE-
induced synaptic injury using our novel conditional RAGE
knockout mice targeted to cortical neurons as well as
transgenic mice that overexpress signal transduction-defi-
cient mutants of RAGE in neurons. Given that neuronal and
non-neuronal cells in the brain may contribute to AGE-induced
sustained neuronal and synaptic stress and dysfunction, we
assessed the impact of global RAGE deletion in this setting
and further delineated the mechanism by which RAGE-
dependent activation of p38 MAP kinase potentiates AGE-
insulted synaptic injury.
Results
Generation and characterization of conditional neuronal
RAGE selective knockout (nRKO) mice. We developed a
model system in which neuronal expression of RAGE, in
particular in the brain region responsible for learning and
memory, is deleted so that consequences of receptor–ligand
interaction could be assessed in an AGE-rich environment.
To this end, we have recently created Cre recombinase
RAGE null mice, termed Tg nRKO mice, crossing neuronal-
targeted and region-restricted Tg mice that express Cre
recombinase in the entire forebrain under the control of the
forebrain-specific calcium-calmodulin-dependent kinase II
(CAMKIIa, CK2) promoter34 to generate deletion of neuronal
RAGE in the entire hippocampus and cortex. We used two
Cre-loxP systems to generate the targeting vector and the
RAGE/flox mice (performed by Ozgen Inc., Bentley DC,
WA, Australia). Figure 1a demonstrates a targeting vector
containing the 50 homology arm, the 30 homology arm, and
loxP arm. Two loxP sites flanking RAGE exons 2–4 allow for
Cre-mediated deletion using Cre recombinase (Figure 1b).
Excision of exons 2–4 by Cre recombinase results in a frame
shift and early stop codon from the mouse RAGE sequence,
which block RAGE expression. We first made homozygous
RAGE floxed allele mice (RAGE flox/flox); then RAGEflox/flox
mice were crossed with neuronal target CK2 mice to
generate nRKO mice (RAGEflox/flox/CK2-Cre), which were
then verified by analysis of tail DNA with PCR amplication
using primers for flox (700 bp) and Cre transgene (300 bp)
(Figure 2a). Immunoblotting of cortical homogenates with
anti-RAGE antibody showed significant reduction of RAGE
expression levels in cerebral cortex of nRKO mice compared
with non-Tg mice (B80% reduction versus non-Tg brain,
Po0.01) (Figure 2b). Incomplete suppression of RAGE
expression was due to brain homogenates, which contained
non-neuronal cells. RAGE expression levels were not altered
in cerebellum homogenates (Figure 2c). Confocal micro-
scopy with double immunostaining of RAGE and MAP2
clearly demonstrated that there was virtually no RAGE signal
in MAP2-positive neurons in cortex (Figures 2d–e) and
hippocampus (Figure 2f) of nRKO mice, thereby verifying
RAGE depletion in cortical neurons in the brain of nRKO
mice.
Immunochemical characterization of Ne-carboxymethyl-
lysine (CML) in AGE preparation. Of all forms of AGEs,
CML is a major glycation product known to be stable
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Figure 1 Targeted construct cassette. Schematic representation of the strategy used for conditional knockout of the RAGE gene by excision of exons 2–4 of the mouse
RAGE gene. (a) Annotated (MacVector 9.5.3) display of the locus identifying the region targeted for homologous recombination. The targeting vector was constructed from
three fragments, the 50 homology arm, two loxP sites and the 30 homology arm. PGK-neo selection cassette is inserted downstream of exon 1. The PGK-neo cassette is
flanked by FRT sites and exons 2–4 are flanked by two loxP sites. (b) RAGE flox/flox mice were crossed with neuronal target CK2 mice to generate nRKO mice (RAGEflox/flox/
CK2-Cre). Two loxP sites flanking RAGE exons 2 to 4 to allow for Cre-mediated deletion using Cre-recombinase. Excision of exons 2–4 by Cre recombinase leads to a frame
shift and early stop codon from the mouse RAGE sequence to block RAGE expression
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diabetes-associated complications.21,35 To verify whether
CML was a major component in our AGE preparation, we
prepared AGEs by incubation of bovine serum albumin
(BSA) with glucose 6-phosphate for 6–8 weeks at 37 1C and
then performed immunochemical characterization using a
monoclonal antibody targeting CML adducts. Using Coomassie
blue dye for rapid reversible staining of protein bands in gel,
we observed co-migration of BSA and AGE-modified BSA at
B66 and B70 kD, respectively (Figure 3a). The increase in
molecular weight of glycated BSA is due to AGE modification,
which results in intramolecular crosslinking. Immunoblotting
of the same preparation of BSA and AGE-BSA using specific
antibody to CML showed prominent CML immunoreactivity
only in the presence of AGEs, suggesting that BSA was
glycated. In contrast, such immunoreactivity was absent on
BSA without glucose 6-phosphate (Figure 3a). These results
indicate that CML is a major component of our AGE
preparation, used in all our experiments.
AGEs impair hippocampal long-term potentiation (LTP).
To determine direct effect of AGEs on synaptic function, we
examined synaptic transmission under basal condition and
during LTP, a form of synaptic plasticity that is widely studied
as a cellular model for synaptic function, in hippocampal
slices from non-Tg mice treated with AGEs or BSA
as a control. In vehicle-treated slices, BSA alone did
not alter LTP (228.8±17.04% versus 223.0±7.95% in
BSA-treated slices, P40.05, Figures 3b and c) or basal
synaptic transmission (BST) as measured by input–output
measurement (Figure 3d). AGE treatment significantly
reduced LTP in a concentration-dependent manner
(180.9±15.36%, 139.1±10.42%, and 124.9±7.96% for
50, 100, and 200 mg/ml AGEs, respectively, versus
220.9±20.75% for 100mg/ml BSA, Po0.01, Figures 3e
and f). There were no significant differences of field-
excitatory post-synaptic potential (fEPSPs) in CA1 stratum
radiatum between AGE- and BSA-treated slices, indicating
that AGEs did not affect normal BST in hippocampal
synapses (Figure 3g). These results demonstrate that AGEs
impair long-term synaptic plasticity.
RAGE deficiency rescues AGE-induced LTP deficits. To
directly determine the impact of RAGE on AGE-mediated
reduction of LTP, we first recorded LTP in hippocampal slices
from global RAGE depletion (RKO) and non-Tg mice treated

























































































Figure 2 Characterization of transgenic nRKO mice with RAGE deletion in cortical neurons. (a) Transgenic nRKO mice were identified from tail DNA based on PCR
amplication using primers for flox (700 bp) in upper panel, and CK2-Cre (300 bp) in the lower panel. Lane 1 indicates RAGEflox/flox (non-Tg ) mice with negative Cre transgene
and lanes 2-3 denotes nRKO mice carried with both flox and Cre (RAGEflox/flox/CK2-Cre ). (b and c) Immunoblotting of cortical homogenates (b) and cerebellum (c) from the
indicated Tg mice for RAGE. Tubulin was used as a protein-loading control. (d–f) Representative images of double immunostaining for RAGE and MAP2 in cortex (d and e)
and hippocampus (f). Confocal microscopy images showing RAGE deletion in cortical neurons labeled with positive MAP2 as a neuronal marker. Enlarged large images of
neurons derived from the corresponding cells are shown in the frame of panel (e). Scale bar¼ 50mm
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slices compared with non-Tg slices in the presence of BSA
(224.3±17.81% versus 208.8±19.50%, P40.05, Figures
4a and e). However, RAGE deficiency largely protected
hippocampal slices against LTP decreases with AGEs
exposure (184.5±9.73% versus 131.1±7.53%, Po0.01,
Figures 4a and e), suggesting that RAGE deficiency
improves synaptic transmission. Because RAGE is
expressed in neuronal and non-neuronal cells in the brain,
we next examined the contribution of neuronal RAGE to
AGE-mediated synaptic function. We treated neurons from
hippocampal slices from nRKO mice (with depletion of
RAGE) cortices with AGEs and BSA for at least 60 min,
and then we recorded LTP. Slices from both nRKO or non-Tg
mice showed similar LTP in the presence of BSA
(240.2±9.41% versus 208.8±19.50%, P40.05, Figures
4b and e). In contrast, nRKO slices significantly suppressed
LTP decline induced by AGEs as compared with non-Tg
slices (191.6±15.55% versus 131.1±7.53%, Po0.01,
Figures 4b and e). These results indicate that successful
blockade of neuronal RAGE protects from AGE-impaired
synaptic function.
RAGE functions as a signal transduction receptor
for AGEs and Ab, activating multiple downstream
intracellular pathways.27,28 Thus, we evaluated the effect
of RAGE signaling in neurons on AGE-induced LTP using
hippocampal slices from DN-RAGE mice expressing signal
transduction-deficient mutants of RAGE (which were targeted
to neurons to determine RAGE-dependent signaling).
Notably, DN-RAGE slices were significantly resistant to
AGE-mediated reduction of LTP as compared with non-Tg
slices (167.0±12.66% versus 131.1±7.53%, Po0.01,
Figures 4c and e). Figure 4d shows representative traces
taken 1 min before (black line) and 60 min after LTP induction
(gray line). BST was not affected in RAGE knockout or mutant
mice (Figure 4f). These results indicated that RAGE-
dependent signaling in neurons contributes to AGE-induced
synaptic malfunction.
Mitogen-activated protein kinase 38 (MAPK p38) activation
is involved in AGE-induced synaptic deficit. To deter-
mine which molecular players underlie AGE effects on








































































































































Figure 3 AGE-impaired long-term potentiation (LTP). (a) Determination of the degree of CML in AGE preparation. Protein (2 mg) from BSA was incubated with glucose
6-phosphate for 8 weeks at 37 1C and then subjected to SDS-PAGE. Protein bands were stained by Coomassie Blue (left). Glycation was detected by immunoblotting with
antibody to CML (right). Lane 1, BSA; lane 2, AGE-modified BSA. (b) BSA alone did not affect LTP. Inserts show representative traces of fEPSP in slices treated with vehicle or
100mg/ml BSA before y-burst stimulation (black line) and at the end of 1 h recording (gray line). (c) Residual potentiation from the fEPSP slopes occurring over the last 5 min
of LTP recordings. (d) BSA did not affect basal synaptic transmission (BST). (e) Effect of AGE on LTP. Hippocampal slices were perfused with AGE (50, 100, and 200mg/ml) or
BSA (100mg/ml) for 1 h and then recorded LTP. N¼ 8–11 slices from 3 to 5 mice. (f) Residual potentiation from the fEPSP slopes occurring over the last 5 min of LTP
recordings. (g) The BST of hippocampal synapses was recorded from the indicated groups of mice
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N-terminal kinases (JNK) in hippocampal slices upon
exposure to AGEs, because these kinases are activated
(increased phosphorylation levels) in several pathological
conditions and synaptic plasticity;36,37 further, p38 is a key
mediator of RAGE-mediated signal transduction.37 Using
antibodies to phosphorylated forms of p38 and JNK with
hippocampal extracts after exposure to AGEs and high
frequency stimulation, we estimated activation of these two
kinases. Addition of AGEs to non-Tg hippocampal slices
significantly increased p38 phosphorylation compared with
BSA addition, but treatment with AGEs did not affect total
p38 levels (Figure 5a). Densitometry analysis of the
combined immunoreactive bands revealed a significant
increase in p38 phosphorylation by 1.5–1.7-fold when
normalized to total p38 versus that of BSA-treated controls
(Figure 5b). AGEs treatment did not affect JNK phosphoryla-
tion (Figure 5c).
To further evaluate the effect of p38 activation on
AGE-mediated LTP impairment, we perfused hippocampal
slides with SB203580, a specific p38 inhibitor, along with
AGEs. Clearly, SB203580 application significantly blocked
induction of p38 phosphorylation in the presence of AGEs
compared with the AGE treatment alone without p38
inhibitor (SB203580) (Figure 5d). Consequently, AGE-impaired
hippocampal LTP was restored by inhibition of p38 with
SB203580 perfusion (Figures 5e and f). These results
suggest that AGE-mediated p38 activation contributes to
synaptic injury.
RAGE deficiency blocks AGE-induced p38 activation.
To determine whether RAGE is a key player in AGE-
mediated p38 activation, we assessed the effect of RAGE
deletion on p38 phosphorylation induced by AGEs. Slices
from RKO mice showed completely suppressed p38 activa-
tion as shown by decreased p38 phosphorylation compared
with non-Tg slices with AGEs (Figures 6a and b). Further,
RAGE depletion specifically targeted to cortical/hippocampal
neurons or neuron-targeted expression of a signal transduc-
tion-deficient mutant of RAGE abolished AGE-induced p38
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Figure 4 Effect of RAGE depletion on AGE-induced LTP impairment. (a–c) LTP was recorded in hippocampal slices from non-Tg, RKO (a), nRKO (b), and DN-RAGE (c)
mice after 1 h perfusion with BSA or AGEs (100 mg/ml). RAGE deletion alone did not alter LTP in the presence of BSA. In contrast, LTP was increased in slices from RKO,
nRKO, and DN-RAGE mice compared with non-Tg slices in the presence of AGE. (d) Representative traces of fEPSP in slices treated with vehicle or 100mg/ml BSA before
y-burst stimulation (black line) and after 1 h (gray line). (e) Residual potentiation from the fEPSP slopes occurring over the last 5 min of LTP recordings. (f) There were no
significant differences in BST among indicated groups. N¼ 8–11 slices from 3 to 5 mice
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for phospho-p38 normalized to total p38 verified significantly
reduced phospho-p38 immunoreactive bands in slices from
RKO, nRKO, and DN-RAGE compared with non-Tg slices
with AGE treatment (Figures 6a and b). These data indicate
that RAGE deficiency prevents AGE-induced p38 activation.
p38 activation of signal transduction is a consequence of
AGEs–RAGE interaction on neurons, contributing to neuronal
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Figure 5 Effect of AGEs on p38 activation. Brain slices were perfused with BSA or AGEs (100mg/ml) for 1 h and then subjected to immunoblotting for phosphorylation and
total p38 (a and b) or JNK (c). (a) Immunoblotting of brain homogenates from AGE- or BSA-treated slices for phosphorylation and total p38. Tubulin was used as the neuronal
protein-loading control. (b) Densitometry of the combined phospho-p38 immunoreactive bands relative to total p38. (c) Densitometry of phospho-JNK immunoreactive bands
relative to total JNK in slices treated with BSA or AGE. Data are expressed as fold increase relative to the BSA-treated control group. The lower panel shows representative
immunoblots for the indicated proteins. N¼ 3–5 per group of treatment. (d) Effect of p38 inhibitor (SB203580) on AGE-induced p38 phosphorylation. Densitometry of
phospho-p38 immunoreactive bands relative to total p38 in non-Tg slices perfused with AGEs with or without SB203580. Representative immunoblots for the indicated protein
are shown in the lower panel. (e) Effects of p38 inhibitor (SB203580) on AGE-induced LTP deficits in hippocampal slices. Slices were perfused with vehicle, AGEs (100mg/ml),
SB203580 (1mM), or AGEs plus SB203580 for 1 h before LTP recording. n¼ 8–11 slices per group of treatment. Upper panel shows representative traces of fEPSP in slices
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Figure 6 Effect of RAGE deficiency on AGE-induced p38 activation. Hippocampal slices from the indicated Tg mice and non-Tg mice were perfused with AGEs for 1 h and
then subjected to immunoblotting for phospho- and total-p38. (a) Immunoblots for phospho- and total-p38 with tubulin used as protein-loading control. (b) Densitometry of
phospho-p38 immunoreactive bands normalized by total p38 using the NIH Image J software. N¼ 3–5 mice per group
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Effect of AGEs-RAGE interaction on synaptic density.
To determine the extent of AGE-induced synaptic damage in
AGE-insulted neurons, we first analyzed the effect of AGEs
on synaptic density. Synapses were identified as synapto-
physin-positive clusters attaching to dendrites labeled with
MAP2 marker. Recruitment of the presynaptic protein,
synaptophysin, to form synaptophysin-positive clusters is
rapid and synaptic activity-dependent.38 Two hours after
AGEs treatment, synaptophysin density in hippocampal
neurons was not altered compared with BSA-treated control
cells, whereas hippocampal neurons exposed to AGEs
for 48 h showed synaptophysin-positive cluster reduced by
50–60% (Figure 7a). Importantly, RAGE-deficient neurons
largely reversed AGE-induced decrease in synaptic density
(Figure 7b). These data indicate that RAGE depletion
rescues AGE-induced synaptic loss.
Discussion
In addition to its ability to directly alter the structure and
function of targeted proteins within cells that causes cell or
tissue damage, emerging evidence has also demonstrated
AGEs as a signaling ligand, interacting with RAGE; AGEs
elicit signal transduction changes that adversely affect
numerous peripheral organs.39–41 Although AGE accumula-
tion is increased in cortical neurons, hippocampal pyramidal
neurons, astrocytes, and other glial cells in aging and AD
brain,4,42,43 the direct effect of AGEs–RAGE interaction on
brain function, in particular on changes in synaptic structure
and function, remains largely unknown. Using our novel
transgenic mouse model with neuronal expression of RAGE
signaling and lacking neuronal RAGE in the forebrain for
evaluation of synaptic transmission and plasticity (almost
every brain function relays on synaptic transmission), we
provide convincing evidence to support a pivotal role of
neuronal AGEs–RAGE interaction on MAPK P38 activation,
hippocampal plasticity deficit, and synaptic injury.
We first demonstrated detrimental effect of AGEs on
synaptic structure and function. The addition of AGEs
significantly impaired synaptic plasticity by reducing LTP
and synaptic morphology. LTP is important to long-term
synaptic plasticity, and altered synaptic morphology (synaptic
loss), which likely contributes to the learning and memory
deficits seen in age-related cognitive decline. Aging is
characterized by anatomical and functional decline across
multiple organ systems. AGEs are found in the serum and
accumulate in the tissue during aging;5,44,45 this accumulation
is accelerated in pathological conditions such as diabetes and
neurodegenerative diseases, including AD. Increased levels of
AGEs are reported in the cortical neurons of older adults and
are positively correlated with the severity of cognition impair-
ment.46 The serum AGE levels were significantly increased
in diabetic patients (equivalent to 30–88mg/ml AGE-BSA
versus 12mg/ml AGE-BSA in non-diabetic patients).6–8 Our
previous studies demonstrated that AGE albumin (1mM,
equivalent to 66.5mg/ml) resulted in oxidant stress and
activation of transcription factor NF-kB in vitro and in vivo, a
process involving the AGE-binding protein RAGE. Notably,
AGE-induced cellular perturbation and oxidant stress were
blocked by antibodies to RAGE.47 Thus, increased levels of
AGEs and of their receptor, RAGE, play an important role in
AGE-mediated cellular perturbation during the pathogenesis of
age-related processes and diabetes. The concentration of
AGEs used in the present study correlates with that of the
pathological condition found in human disease.
In our study, perfusion with AGEs in hippocampal slices
impaired LTP in a concentration-dependent manner, consis-
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Figure 7 Effect of RAGE deficiency on AGE-induced synaptic loss. (a) Non-Tg neurons were treated with 100mg/ml AGEs or BSA for 2 and 48 h and then subjected to
immunostaining with synaptophysin and MAP2. Quantification of positive synaptophysin clusters per micron of dendrites was significantly decreased in AGE-treated cells
compared with BSA-treated cells. (b) RAGE-deficient neurons largely protected AGE-induced loss of synaptophysin-positive clusters compared with non-Tg neurons in the
presence of AGEs. Lower panel shows representative images of synaptic staining. Synapses were visualized by synaptophysin staining (green) and dendrites by MAP2
staining (red). Scale bar¼ 50mm
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AGE treatment by stereotaxic injection into the brain led to
synapse and memory impairments.48 However, the impact of
neuronal RAGE on AGE-induced synaptic damage is unclear.
Given that AGE formation and accumulation is accelerated in
the brain of diabetic and AD subjects, AGEs–RAGE interac-
tion could be an important target in the search for agents
that halt disease acceleration or exacerbation relevant to
diabetes- and AD-related cognitive decline and dementia.
Next, using our genetic RAGE depletion mouse model, we
investigated the effect of RAGE-dependent signaling on
AGE-insulted synaptic injury. AGE perfusion-induced LTP
reduction may be caused by varying factors; for example,
one cause involves AGE binding to RAGE receptors,
and another is via protein crosslinking-induced cellular
malfunction. Genetic deletion of RAGE offers us the ability
to identify AGEs-RAGE interaction in AGE-induced synaptic
impairment. We recorded normal LTP readings in brain slices
of our global RAGE null mice treated with vehicle compared
with non-transgenic littermates, indicating that genetic RAGE
deletion does not significantly alter synaptic structures
important for LTP induction and expression under normal
physiological conditions. Notably, RAGE deficiency protects
against AGE-induced LTP deficits. Similarly, our data
demonstrate the protective effect of RAGE depletion on
AGE-induced synaptic loss. Although our results did not
exclude other effects of AGEs such as protein crosslinking,
we clearly demonstrated that AGEs-RAGE interaction is
involved in AGE-induced synaptic injury.
As RAGE is expressed in neurons and non-neuronal cells
(i.e., glial, endothelial cells, and pericytes of the blood–brain
barrier),49,50 the results obtained from global RAGE knockout
mice do not delineate which cell type(s) is (are) important in
AGE-induced synaptic plasticity impairment. Therefore, we
created transgenic mice with nRKO and a signal transduction-
deficient mutant of RAGE (DN-RAGE) specifically in the
forebrain, including the hippocampus, to address the question
of whether the activity of neuronal RAGE is responsible
for AGE-induced hippocampal LTP reduction. Indeed, our
findings clearly showed that nRKO and DN-RAGE brain
slices were largely resistant to disruption of LTP via AGE
exposure, implicating the involvement of neuronal RAGE in
mechanisms underlying AGE-induced synaptic dysfunction.
Further, introduction of neuronal DN-RAGE or RAGE
deficiency in cortical neurons (nRKO) failed to completely
prevent AGE-impaired LTP compared with perfusion with
BSA. These results suggest that non-neuronal RAGE
(i.e., RAGE expression in microglia, astrocyte, or endothelial
cells) may be involved in AGE-induced synaptic dysfunction.
Future studies will be required to investigate the role of
non-neuronal RAGE in synaptic failure induced by AGEs.
Regardless, our studies delineate the mechanisms involving
neuronal RAGE-mediated signal transduction in AGE-
induced synaptic dysfunction and degeneration. Neurons
are susceptible to AGE insults via direct AGEs–RAGE
interaction contributing to synaptic dysfunction and
degeneration.
Finally, our results suggest that the MAPK P38 signaling
pathway is critical for AGEs–RAGE-induced synaptic damage.
AGE-induced LTP decline was attenuated in DN-RAGE slices
with a signal transduction-deficient mutant of RAGE, indicating
the contribution of RAGE-dependent signaling to AGE-induced
synaptic impairment. Signaling cascades activated after
ligand–RAGE interaction include pathways those of p21ras,
extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and
JNK, Rho GTPases, phosphoinositol-3 kinase, GSK-3b,
and the JAK/STAT (signal transducer and activator of
transcription).51,52 Activation of different protein kinase
cascades may represent a principal target of RAGE activation
for control of synaptic plasticity.37,53
In particular, we considered the potential involvement of
two different kinases, JNK and p38 in LTP inhibition based
on our previous study showing that p38 and JNK activation
are required for LTP inhibition induced by Ab–RAGE
interaction.37,54 Hippocampal slices perfused with AGEs
showed increased p38 activity but no change in JNK,
suggesting the involvement of p38 activation in p38
signaling and the AGE-induced synaptic plasticity deficits.
Indeed, the addition of p38 inhibitor prevented AGE-induced
p38 activation and LTP impairment. Note, RAGE depletion
blocked induction of p38 phosphorylation and restored
defects in synaptic plasticity and density from AGE
exposure. Our results indicate that neuronal AGEs–RAGE
interaction activates p38 MAK kinase, which in turn leads to
synaptic dysfunction.
We further observed that if AGEs level remained chronically
high, synapses become structurally damaged. Using hippo-
campal neuronal cultures, we showed that short-term AGEs
exposure (for 2 h treatment) barely affected synaptic struc-
ture, whereas long-term treatment of AGEs (for 48 h) caused
significant changes in synaptic density. Importantly, RAGE
deletion rescues AGE-induced synapse loss. These data
indicate that neuronal AGEs–RAGE interaction has functional
(long-term plasticity) as well as structural effects on synapses,
which may be important in the learning and memory deficit
present in age-related dementia and age-associated neuro-
degenerative disease.
In summary, we provide substantial evidence of the
protective effect of RAGE depletion on AGE-induced altera-
tions in synaptic plasticity and density. Genetic depletion of
RAGE and RAGE signaling in cortical neurons blocks AGE-
mediated activation of p38 MAP kinase signal transduction
with LTP deficits. We propose that AGEs-RAGE-dependent
activation of p38 MAP kinase is responsible for AGE-induced
synaptic damage. Blockade of AGEs-RAGE axis may protect
against the impaired cognitive function in aged subjects with




Generation and characterization of conditional neuronal knockout of
RAGE mice
Targeted disruption of mouse RAGE gene. We used the Cre-loxP system to
generate the targeting vector and the RAGE/flox mice (performed by Ozgen Inc.).
The targeting vector consists of three fragments, namely, the 50 homology arm,
30 homology arm, and loxP arm. Two loxP sites flank RAGE exons 2–4 to allow for
Cre-mediated deletion using Cre recombinase. Excision of exons 2–4 by Cre
recombinase led to a frame shift and early stop codon from the mouse RAGE
sequence. A PGK-neo selection cassette was inserted downstream of exon 1.
The PGK-neomycin resistance selection cassette is flanked by FRT sites and was
deleted using FLPe recombinase (Figure 1, targeting vector).
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Generation of neuronal deletion of RAGE mice (nRKO). After deletion of the PKG-
neo cassette by crossing with FlpE-deletor C57BL/6 mice (Ozgen Inc.) to eliminate
the neomycin resistance selection cassette (PKG-neo), the floxed RAGE allele
was generated. To generate Cre recombinase RAGE null mice (RAGEflox/flox/CK2-
Cre, namely, nRKO mice), selective for the cortical and hippocampal neuron under
the control of the Camk2a (CK2) promoter, RAGE/flox mice were bred with
neuronal-targeted and region-restricted transgenic mice that express Cre
recombinase in the entire forebrain (L7Ag13 line) under the control of the
forebrain-specific CAMK II promoter.34 Cre mice (L7Ag13 line) were kindly
provided by Dr. Eric Kandel (Columbia University, New York, NY, USA). Floxed
RAGE mice were identified by PCR with primers (forward: 50-TACCGAGTCC
GAGTCTACCGTAAG-30 and reverse: 50-TCTCCTGGTCTCTTCCTTCACGAG-30)
to amplify a 551-bp fragment from the wild-type (WT) allele and a 700-bp fragment
from the floxDneo allele. The Cre transgene was identified by PCR primers
(forward: 50-CTTCATCGTCGGTCCG-30 and reverse: 50-ACATTCTCCCACCGTC-30)
to amplify a 300-bp fragment. Specific neuronal RAGE knockout was further
confirmed by western blotting of cortical and cerebellum homogenates using rabbit
anti-RAGE antibody (generated in our Lab and used in our previous study55).
All transgenic mice were of the C57BL/6 strain. The Institutional Animal Care and
Use Committee of the University of Kansas approved all protocols. Male
transgenic mice and their littermate controls were used for the in vitro
electrophysiology experiments.
Homozygous RAGE-null mice (RKO) and transgenic mice with
cytosolic dominant-negative RAGE (DN-RAGE)
We generated and characterized homozygous RAGE-null mice (RKO) as
described previously.33,56 In addition, we used transgenic mice with signal
transduction-deficient mutants of RAGE in which the cytosolic domain of the
receptor was deleted, thereby imparting a dominant-negative (DN)-RAGE effect,
targeted to neurons (DN-RAGE) driven by the platelet-derived growth factor-B
chain promoter. DN-RAGE mice were previously characterized, demonstrating
localization of DN-RAGE in cortical neurons.54
Preparation of AGEs
We generated AGEs by incubating BSA (25 mg/ml) with 250 mM glucose
6-phosphate at 37 1C for 6–8 weeks in 0.1 M phosphate buffer containing 1.5 mM
PMSF, 0.5 mM EDTA, and 1 mM azide.57 The control preparation (BSA) was
treated identically with the exception that glucose 6-phosphate was omitted.
We dialyzed preparations with phosphate buffer to remove free glucose, EDTA,
PMSF, and azide after incubation. The degree of glycation was determined
by immunoblotting using antibody to CML (TransGenic Inc., Kobe, Japan).
Coomassie blue staining of gel was used as a protein-loading control.
Electrophysiological studies
Electrophysiological studies were performed as described.54,58 Transverse
hippocampal slices (400mm) were cut from the mouse brain, maintained in an
interface chamber at 29 1C, and perfused with artificial cerebrospinal fluid (aCSF)
continuously bubbled with 95% O2 and 5% CO2. The aCSF composition (in mM)
was: 124.0 NaCl, 4.4 KCl, 1.0 Na2HPO4, 25.0 NaHCO3, 2.0 CaCl2, 2.0 MgCl2, and
10.0 glucose. fEPSP was recorded for the CA1 region of the hippocampus by
placing the stimulating electrode at the level of the Schaeffer collateral fibers and
recording electrode in the CA1 stratum radiatum. BST was assayed by plotting the
stimulus voltage (V) against slopes of fEPSP to generate input–output relations.
For LTP experiments, a test pulse was applied every minute at an intensity
evoking B35% of the maximum evoked response. LTP was induced using y-burst
stimulation (4 pulses at 100 Hz, with bursts repeated at 5 Hz and each tetanus,
including three 10-burst trains separated by 15 s). Responses were recorded for
60 min after tetanization and measured as fEPSP slope expressed as the
percentage of baseline.
Immunoblotting analysis
Brain slices were lysed in extraction buffer (10 mM Tris-HCl (pH 7.4), 100 mM
sodium chloride, 1 mM EDTA, 1 mM EGTA, 1 mM sodium fluoride, 20 mM sodium
pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100, 10% glycerol,
0.1% SDS, 0.5% deoxycholate, 1 mM PMSF) containing protease inhibitor mixture
(set V, EDTA-free; Calbiochem, Billerica, MA, USA). Protein extracts were
separated by SDS/PAGE (12% Bis-Tris gel; Invitrogen, Grand Island, NY, USA),
and then transferred to a nitrocellulose membrane (Amersham, Pittsburgh, PA, USA).
After blocking in TBST buffer (20 mM Tris-HCl, 150 mM sodium chloride,
0.1% Tween-20) containing 5% non-fat dry milk (Santa Cruz, Dallas, TX, USA) for
1 h at room temperature, we incubated the membrane, and gently shaking
overnight (at 4 1C) with primary antibodies, followed by incubation with the
corresponding secondary antibody for 1 h at room temperature. We used
antibodies to phosphorylation and total of p38 and JNK (Cell Signaling, Boston,
MA, USA) and tubulin (Sigma, St. Louis, MO, USA). ImageJ software (National
Institutes of Health, Bethesda, MD, USA) was used for analysis of scanned blots
and to quantify intensity of the immunoreactive bands.
Immunohistochemical analysis
Mice were anesthetized by an intraperitoneal injection of a mixture of ketamine
(50 mg/kg) and xylazine (10 mg/kg) and perfused transcardially with 0.9% sodium
chloride for 10 min. Mouse brains were fixed in 4% paraformaldehyde at 4 1C for 2
days. Floating coronal sections of 30-mm thicknesses were cut by vibratome (Leica
VT 1000S, Wetzlar, Germany), collected, and immersed in wash buffer (0.1 M
sodium phosphate, 0.5 M sodium chloride, Triton X-100, pH 7.4) for 30 min. After
preincubation for 1 h in blocking solution (10% normal goat serum, 0.3% Triton
X-100 in PBS), we incubated sections overnight at 4 1C with primary antibodies,
using rabbit anti-RAGE IgG (3.5mg/ml, generated in our Lab) and mouse anti-
MAP2 (1 : 10 000, Chemicon, Billerica, MA, USA) for cortex and hippocampus
staining. Sections were then incubated with Alexa Fluor 594-conjugated goat anti-
rabbit IgG and 488 goat anti-mouse IgG secondary antibodies (1 : 1000,
Invitrogen) for 1 h at room temperature. Nuclei were stained by DRAQ5 (5 mM,
Cell Signaling) for 5 min at room temperature.
Measurement of synaptic density
Neuronal culture. We prepared hippocampal neurons from day 1 non-Tg or RKO
mice in the C57/BL6 background as described previously,59 culturing neurons in
neurobasal medium supplemented with 1 X B27, 600mM L-Glutamine and
penicillin–streptomycin. At day 10 in vitro, neurons from both Tg mice were treated
with 100 mg/ml of AGEs; BSA was used as a control in neurobasal medium
supplemented with 0.5 X B27 for 2 and 48 h, respectively.
Immunostaining of cultured neurons. After the various treatments, neurons were
fixed with 4% ice-cold paraformaldehyde for 5 min and then permeabilized with
PBS containing 0.1% Triton and 5% goat serum for 1 h at room temperature
followed by incubation with primary antibodies (rabbit anti-synaptophysin IgG
(1 : 5000, Dako) and mouse anti-MAP2 IgG (1 : 10 000, Chemicon)) to visualize
dendrites at 4 1C for 16 h. Neurons were incubated with both Alexa Fluor
488-conjugated goat anti-rabbit IgG and 594 goat anti-mouse IgG (1 : 1000,
Invitrogen) for 1 h at room temperature. After washing with PBS, neurons were
covered with Vectashield mounting medium (H-1000, Vector Laboratories,
Burlingame, CA, USA). Images were taken at equal exposure for all the
different groups at  63 oil lens under a confocal microscopy (Leica) and
analyzed by the Universal Metamorp Image Program (Molecular Devices,
Sunnyvale, CA, USA).
Synaptic density of cultured neurons was measured by counting the number of
synaptophysin-positive clusters in secondary branches and puncta per micron
of dendrite (presented as the number of synaptophysin clusters per micron of
dendrite) and calculated by dividing the length of the dendrite. The experiments
were performed by investigators blinded to the information about genotype and
treatment. Codes for the ID of group cells were not disclosed until completion of
image analysis.
Statistical analysis
One-way ANOVA was used for repeated measure analyses followed by Fisher’s
protected least significant difference for post hoc comparisons. We used StatView
5.0.1 Windows software (SAS Institute, Cary, NC, USA), and results are reported
as mean±S.E.M. Po0.05 was considered significant.
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